Le Lézard
Classified in: Health, Science and technology
Subject: IPO

Karuna Therapeutics Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering


Karuna Therapeutics, Inc. today announced that it has previously confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended ("Securities Act"). This announcement is being issued in accordance with Rule 135 under the Securities Act.


These press releases may also interest you

at 22:30
Seattle Genetics, Inc. today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock at a price to the public of $70.00 per share. All of the shares are being sold by Seattle Genetics. The gross proceeds to...

at 21:33
Healthcare providers are focused on delivering care. That means always seeking better ways to improve patient outcomes, make reporting easier, and meet financial goals. It's a big job that never ends. That's why  Prista Corporation Chief Mission...

at 21:18
Global Vitamin D Testing Market: About this market Vitamin D is needed to maintain serum calcium and phosphate concentration to regularize the mineralization of bone and tooth. This vitamin D testing market analysis considers sales from both...

at 21:07
Digital Therapeutics and Their Impact on HealthcareSummaryRead the full report: https://www.reportlinker.com/p05795614/?utm_source=PRN Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx)...

at 21:00
Is there some way to bring a software as a medical device (SaMD) product to market faster? The answer is yes, with the Software Precertification Program. The pre-cert pathway regulatory model expedites pre-market approval while assessing the safety...

at 20:50
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2019 on Thursday, August 1, 2019, following the close of the market. The company will discuss...



News published on 26 april 2019 at 02:05 and distributed by: